Latest Regulation News

Monash IVF Group reported steady FY25 financial results with revenue and EBITDA growth, while managing clinical incidents and a CEO transition. The company outlines cautious FY26 guidance amid industry headwinds.

Dart Mining NL’s DTMOC securities have been suspended from trading by the ASX due to non-compliance with key listing rules, raising questions about the company’s regulatory standing.

Latitude Group Holdings reported a robust half-year to June 2025, with revenue climbing 13.3% and statutory profit soaring 341%, while navigating ongoing regulatory investigations related to a 2023 cyber incident.

Brazilian Critical Minerals secures robust support from Amazonas state and local authorities for its Ema Rare Earth Project, advancing environmental permitting with unanimous community approval.

Cuscal Limited reported a 6% revenue increase for FY25 and announced a strategic acquisition of Indue, alongside a leadership change and a higher final dividend.

Australian Vintage Limited reported a strong FY25 with significant profit growth despite flat revenue, underpinned by innovation and cost-cutting initiatives. The company aims for positive free cash flow in FY26, propelled by global brand expansion and operational efficiencies.

Trading in Aspermont Limited shares has resumed following the ASX's immediate lifting of the suspension after the company released a key announcement.

Objective Corporation reports robust FY2025 results with strong recurring revenue growth and deepening AI integration, setting ambitious targets for FY2026.

Objective Corporation reported solid FY2025 results with 5% revenue growth and a 15% jump in Annualised Recurring Revenue, underpinned by significant R&D investment and a strong subscription model.

Objective Corporation Limited reported a solid 5% revenue increase to $123.5 million and a 13% rise in net profit after tax to $35.44 million for FY2025, alongside a strategic acquisition that broadens its e-planning software portfolio.

Peet Limited reported a robust FY25 with a 60% surge in net profit after tax and declared a higher fully franked dividend, underpinned by strong sales and improved capital management. The company is also undertaking a strategic business review while navigating leadership transitions.

Medical Developments International has reported a remarkable turnaround in FY25, posting a net profit after tax and securing paediatric approval for its flagship product Penthrox in Europe.